Data Provided by Refinitiv. Minimum 15 minutes delayed.
We are a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address fibrotic diseases and acute organ injuries. Our goal is to transform the treatment paradigm for patients suffering from these potentially life-threatening conditions for which there are no approved medicines or where existing approved medicines have limitations. Our lead product candidate is ANG-3070, a highly selective oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, particularly in the kidney and lung. ANG-3070 has demonstrated activity as an anti-fibrotic agent in a variety of animal models. A Phase 1 healthy volunteer study demonstrated ANG-3070 to have a favorable safety and PK profile, producing plasma concentrations which exceeded those demonstrating activity in animal models of proteinuric kidney diseases. Enrollment is ongoing in a dose-finding Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases. ANG-3777 is a hepatocyte growth factor (HGF) mimetic. We are evaluating next steps in this program based upon the full data set from the ANG-3777 Phase 2 GUARD trial in patients at risk for acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass (CSA-AKI). We are advancing multiple preclinical programs, including our inhibitor of rho kinase 2 (ROCK2) and our CYP11B2 aldosterone synthase inhibitors.